Related Experiment Video

Updated: Apr 18, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

How I treat mixed-phenotype acute leukemia

Ofir Wolach1, Richard M Stone1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Blood
|January 22, 2015
PubMed

Insights

Mixed-phenotype acute leukemia (MPAL) is a rare, aggressive blood cancer resistant to therapy. Current treatment recommendations include chemotherapy and stem-cell transplant, but further research is needed for targeted therapies.

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Mixed-phenotype acute leukemia (MPAL) is a rare and heterogeneous myeloid or lymphoid malignancy.
  • Historically, MPAL has been described using various terms and classification systems.
  • Current MPAL classification relies on limited lineage-specific markers from the 2008 WHO monograph.

Observation:

  • MPAL in adults often presents with therapeutic resistance, frequently linked to adverse cytogenetic abnormalities.
  • There is a lack of prospective, controlled clinical trials to establish definitive treatment guidelines for MPAL.
  • Limited data suggest an acute lymphoblastic leukemia-like regimen followed by allogeneic stem-cell transplant may be beneficial.

Findings:

  • The addition of tyrosine kinase inhibitors is recommended for MPAL patients with the t(9;22) translocation.
  • The optimal role of immunophenotypic and genetic markers in guiding MPAL chemotherapy and postremission strategies remains unclear.
  • The efficacy of targeted therapies in non-Ph-positive MPAL requires further investigation.

Implications:

  • Improved understanding of MPAL biology and treatment is crucial for this rare leukemia.
  • Further research is needed to develop targeted therapies and optimize treatment strategies for MPAL.
  • Establishing clear diagnostic and therapeutic guidelines will enhance outcomes for MPAL patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

949
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72